Ryan D. Maynard - 23 Feb 2026 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: FHTX
Reported as of: 23 Feb 2026
Net transaction value: +$2,300,000
SEC form: 4
Accepted by SEC: 24 Feb 2026, 16:02:39 UTC
Prior SEC filing: 17 Jun 2025
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael LaCascia, Attorney-in-Fact for Ryan D. Maynard

Key filing fact

Ryan D. Maynard filed Form 4 for Foghorn Therapeutics Inc. (FHTX) on 24 Feb 2026.

Key facts

This page summarizes Ryan D. Maynard's Form 4 filing for Foghorn Therapeutics Inc. (FHTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 16:02.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: +$2,300,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001363984 Primary reporting owner

Maynard Ryan D

Relationship: Chief Financial Officer
Address: 99 COOLIDGE AVENUE, SUITE 500, WATERTOWN
Signature: /s/ Michael LaCascia, Attorney-in-Fact for Ryan D. Maynard
Signature date: 24 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FHTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $2,300,000
Shares: +400,000
Change %
Price: $5.75
Shares after: 400,000
Date: 23 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $5.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 25% of the underlying shares of common stock on February 23, 2027, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested.